DIECI, Maria Vittoria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.379
AS - Asia 2.967
EU - Europa 2.450
SA - Sud America 398
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 81
OC - Oceania 8
Totale 12.389
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.176
SG - Singapore 808
CN - Cina 753
IT - Italia 633
GB - Regno Unito 460
HK - Hong Kong 386
IE - Irlanda 344
BR - Brasile 303
VN - Vietnam 292
BD - Bangladesh 235
SE - Svezia 220
DE - Germania 212
FI - Finlandia 136
CA - Canada 103
RU - Federazione Russa 103
KR - Corea 100
IN - India 98
FR - Francia 94
UA - Ucraina 74
ID - Indonesia 58
TR - Turchia 53
BG - Bulgaria 31
NL - Olanda 29
AR - Argentina 25
JP - Giappone 24
MX - Messico 24
ES - Italia 22
ZA - Sudafrica 22
CO - Colombia 21
IQ - Iraq 20
PL - Polonia 20
CR - Costa Rica 16
PK - Pakistan 16
TW - Taiwan 15
VE - Venezuela 13
CZ - Repubblica Ceca 11
EC - Ecuador 11
MY - Malesia 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
EG - Egitto 10
LT - Lituania 10
SA - Arabia Saudita 10
TN - Tunisia 10
JM - Giamaica 9
AU - Australia 8
HN - Honduras 8
IL - Israele 8
IR - Iran 8
PH - Filippine 8
PR - Porto Rico 8
AT - Austria 7
BE - Belgio 7
DZ - Algeria 7
KE - Kenya 7
NI - Nicaragua 7
JO - Giordania 6
MA - Marocco 6
PY - Paraguay 6
TH - Thailandia 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
RO - Romania 5
SC - Seychelles 5
AL - Albania 4
DK - Danimarca 4
GP - Guadalupe 4
LB - Libano 4
MD - Moldavia 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
PT - Portogallo 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BH - Bahrain 3
BO - Bolivia 3
CW - ???statistics.table.value.countryCode.CW??? 3
DO - Repubblica Dominicana 3
EU - Europa 3
GR - Grecia 3
GT - Guatemala 3
KZ - Kazakistan 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CH - Svizzera 2
CI - Costa d'Avorio 2
EE - Estonia 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MM - Myanmar 2
MT - Malta 2
NG - Nigeria 2
PS - Palestinian Territory 2
SN - Senegal 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
Totale 12.270
Salva come PNG Salva come JPEG
Città #
Ashburn 742
Santa Clara 559
Singapore 534
San Jose 432
Fairfield 391
Hong Kong 380
Dublin 344
Council Bluffs 313
Woodbridge 236
Southend 229
Chandler 219
Hefei 207
Houston 187
Seattle 180
Beijing 139
Ann Arbor 135
Cambridge 134
Dearborn 133
Los Angeles 128
Wilmington 128
Chicago 125
Jacksonville 118
Nyköping 113
London 111
The Dalles 102
New York 95
Helsinki 92
Ho Chi Minh City 90
Seoul 84
Hanoi 80
Milan 74
Dallas 68
Modena 49
Shanghai 47
Munich 46
Rome 46
Jakarta 45
San Diego 45
Lauterbourg 44
Moscow 43
Buffalo 41
Princeton 38
São Paulo 37
Columbus 34
Boardman 33
Sofia 31
Atlanta 26
Phoenix 26
Tampa 26
Eugene 25
Naples 25
Salt Lake City 23
Izmir 22
Bologna 21
Frankfurt am Main 21
Toronto 21
Elk Grove Village 20
Orem 20
Turin 20
Falls Church 18
Florence 18
Mumbai 18
North Bergen 18
Kent 17
Denver 16
Des Moines 16
Tokyo 16
Boston 15
Dong Ket 15
Guangzhou 15
Montreal 15
Norwalk 15
Ottawa 15
Redwood City 15
Lappeenranta 14
Nuremberg 14
Amsterdam 13
Chennai 13
Miami 13
Turku 13
Bremen 12
Redondo Beach 12
San José 12
Warsaw 12
Brooklyn 11
Genoa 11
Newark 11
Taipei 11
Catania 10
Da Nang 10
Fremont 10
Dhaka 9
Haiphong 9
Johannesburg 9
Kunming 9
Lancaster 9
Padova 9
Sterling 9
Surrey 9
Changsha 8
Totale 8.301
Salva come PNG Salva come JPEG
Nome #
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 450
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 443
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 427
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 408
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 383
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 377
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 371
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 343
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 341
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 339
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 328
Immune characterization of breast cancer metastases: prognostic implications. 327
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 320
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 318
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 308
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 286
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 284
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 277
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 268
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 263
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 259
Timing for starting second-line therapy in recurrent ovarian cancer 258
Tumori ginecologici 252
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 252
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 251
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 246
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 232
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 231
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 229
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 224
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 223
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 221
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 207
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 200
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials 196
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT 191
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â € "Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 169
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) 166
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). 158
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 140
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study 137
Pregnancy after Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study 129
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers 120
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients. 114
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 109
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial. 82
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial. 67
PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)]. 56
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives. 55
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer 47
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial. 44
Inclusion of platinum agents in neoadjuvant chemotherapy regimens for triple-negative breast cancer patients: Development of GRADE (grades of recommendation, assessment, development and evaluation) recommendation by the Italian association of medical oncology (AIOM) 38
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 37
Pregnancy after breast cancer in patients with germline BRCA mutations 36
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 36
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications. 35
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology. 33
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study. 25
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer. 23
Totale 12.389
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.822
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022432 0 0 0 0 25 35 32 33 66 60 120 61
2022/2023961 74 97 43 53 63 97 16 60 399 7 25 27
2023/2024572 24 24 30 27 77 39 69 118 25 23 39 77
2024/20251.888 54 27 30 139 360 313 138 103 182 107 188 247
2025/20264.361 271 142 305 425 630 248 534 219 374 429 394 390
2026/20271.559 205 344 340 576 94 0 0 0 0 0 0 0
Totale 12.389